Published in Infect Immun on April 04, 2011
Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design. Front Immunol (2014) 1.13
Host- and microbe determinants that may influence the success of S. aureus colonization. Front Cell Infect Microbiol (2012) 1.03
Wall Teichoic Acid Glycosylation Governs Staphylococcus aureus Nasal Colonization. MBio (2015) 0.93
Obesity and Staphylococcus aureus nasal colonization among women and men in a general population. PLoS One (2013) 0.89
High throughput screening methods for assessing antibiofilm and immunomodulatory activities of synthetic peptides. Peptides (2015) 0.82
RNase 7 in Cutaneous Defense. Int J Mol Sci (2016) 0.78
Interleukin-22 regulates antimicrobial peptide expression and keratinocyte differentiation to control Staphylococcus aureus colonization of the nasal mucosa. Mucosal Immunol (2016) 0.77
Foodborne disease outbreak in a resource-limited setting: a tale of missed opportunities and implications for response. Pan Afr Med J (2016) 0.75
Selected Factors of Innate Immunity in Healthy Individuals with S. aureus Nasal Carriage. Front Microbiol (2016) 0.75
Antimicrobial peptide exposure selects for Staphylococcus aureus resistance to human defence peptides. J Antimicrob Chemother (2016) 0.75
Heme Oxygenase-1 Deficiency Diminishes Methicillin-Resistant Staphylococcus aureus Clearance Due to Reduced TLR9 Expression in Pleural Mesothelial Cells. PLoS One (2017) 0.75
Interleukin-17A (IL-17A) and IL-17F Are Critical for Antimicrobial Peptide Production and Clearance of Staphylococcus aureus Nasal Colonization. Infect Immun (2016) 0.75
The Antimicrobial Peptide Human Beta-Defensin-3 Is Induced by Platelet-Released Growth Factors in Primary Keratinocytes. Mediators Inflamm (2017) 0.75
The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis (2005) 9.80
Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med (2002) 9.01
Host polymorphisms in interleukin 4, complement factor H, and C-reactive protein associated with nasal carriage of Staphylococcus aureus and occurrence of boils. J Infect Dis (2008) 7.45
Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic. J Biol Chem (2000) 6.19
Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol (2003) 3.41
What determines nasal carriage of Staphylococcus aureus? Trends Microbiol (2001) 2.94
Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a "culture rule". Clin Infect Dis (2004) 2.15
Follow-up of Staphylococcus aureus nasal carriage after 8 years: redefining the persistent carrier state. J Clin Microbiol (1999) 2.04
RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin. J Biol Chem (2002) 1.99
Are host genetics the predominant determinant of persistent nasal Staphylococcus aureus carriage in humans? J Infect Dis (2010) 1.92
Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. J Invest Dermatol (2010) 1.89
Determinants of Staphylococcus aureus nasal carriage. Clin Diagn Lab Immunol (2001) 1.80
RNase 7 protects healthy skin from Staphylococcus aureus colonization. J Invest Dermatol (2010) 1.69
Staphylococcus aureus nasal carriage is associated with glucocorticoid receptor gene polymorphisms. J Infect Dis (2006) 1.45
Persistent (not intermittent) nasal carriage of Staphylococcus aureus is the determinant of CPD-related infections. Kidney Int (2005) 1.42
Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol (2006) 1.40
The constitutive capacity of human keratinocytes to kill Staphylococcus aureus is dependent on beta-defensin 3. J Invest Dermatol (2007) 1.32
Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor. J Clin Invest (2006) 1.30
Signal transduction and nuclear responses in Staphylococcus aureus-induced expression of human beta-defensin 3 in skin keratinocytes. Infect Immun (2006) 1.27
Studies on the origin of drug-resistant staphylococci in a mental hospital. Am J Med (1959) 1.26
Defective killing of Staphylococcus aureus in atopic dermatitis is associated with reduced mobilization of human beta-defensin-3. J Allergy Clin Immunol (2008) 1.17
Quantitative studies of nasal carriers of staphylococci among hospitalized patients. J Clin Invest (1961) 1.15
The role of human innate immune factors in nasal colonization by Staphylococcus aureus. Microbes Infect (2007) 1.11
Constitutive expression of the antimicrobial peptide RNase 7 is associated with Staphylococcus aureus infection of the skin. J Infect Dis (2009) 1.08
Both copy number and sequence variations affect expression of human DEFB4. Genes Immun (2010) 1.05
Severity of Staphylococcus aureus infection of the skin is associated with inducibility of human beta-defensin 3 but not human beta-defensin 2. Infect Immun (2010) 1.00
Human hair follicle epithelium has an antimicrobial defence system that includes the inducible antimicrobial peptide psoriasin (S100A7) and RNase 7. Br J Dermatol (2009) 0.97
Microanalysis of an antimicrobial peptide, beta-defensin-2, in the stratum corneum from patients with atopic dermatitis. Br J Dermatol (2008) 0.88
Allergy, parasites, and the hygiene hypothesis. Science (2002) 5.01
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis (2013) 3.46
Short report: Piloting paperless data entry for clinical research in Africa. Am J Trop Med Hyg (2005) 2.85
Placental malaria increases malaria risk in the first 30 months of life. Clin Infect Dis (2008) 2.69
Amplification of Plasmodium falciparum multidrug resistance gene 1 in isolates from Gabon. J Infect Dis (2005) 2.58
Severe falciparum malaria in Gabonese children: clinical and laboratory features. Malar J (2005) 2.35
Fosmidomycin for malaria. Lancet (2002) 2.03
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial. J Infect Dis (2007) 1.99
Microscopic and sub-microscopic Plasmodium falciparum infection, but not inflammation caused by infection, is associated with low birth weight. Am J Trop Med Hyg (2006) 1.88
Long-term treatment of intestinal helminths increases mite skin-test reactivity in Gabonese schoolchildren. J Infect Dis (2004) 1.85
Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. Hepatology (2006) 1.82
Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis (2008) 1.70
Influenza in Africa. PLoS Med (2009) 1.68
Import and spread of Panton-Valentine Leukocidin-positive Staphylococcus aureus through nasal carriage and skin infections in travelers returning from the tropics and subtropics. Clin Infect Dis (2011) 1.67
Increased specific T cell cytokine responses in patients with active pulmonary tuberculosis from Central Africa. Microbes Infect (2005) 1.63
Depressed natural killer cell cytotoxicity against Plasmodium falciparum-infected erythrocytes during first pregnancies. Clin Infect Dis (2004) 1.61
Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. Antimicrob Agents Chemother (2002) 1.59
Increased prevalence of intestinal helminth infection during pregnancy in a Sub-Saharan African community. Wien Klin Wochenschr (2007) 1.58
Impact of increasing consultation fees on malaria in Africa. Wien Klin Wochenschr (2004) 1.56
History and perspectives of medical research at the Albert Schweitzer Hospital in Lambaréné, Gabon. Wien Klin Wochenschr (2007) 1.52
Assessment of volume depletion in children with malaria. PLoS Med (2004) 1.51
Matrix metalloproteinases and their tissue inhibitors (TIMPs) in Plasmodium falciparum malaria: serum levels of TIMP-1 are associated with disease severity. J Infect Dis (2008) 1.51
Socio-economic status is inversely related to bed net use in Gabon. Malar J (2008) 1.46
Adolescence as risk factor for adverse pregnancy outcome in Central Africa--a cross-sectional study. PLoS One (2010) 1.43
Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis (2013) 1.41
Reduced cord blood immune effector-cell responsiveness mediated by CD4+ cells induced in utero as a consequence of placental Plasmodium falciparum infection. J Infect Dis (2005) 1.40
Evidence of decline of malaria in the general hospital of Libreville, Gabon from 2000 to 2008. Malar J (2009) 1.40
Plasmodium falciparum activates endogenous Cl(-) channels of human erythrocytes by membrane oxidation. EMBO J (2002) 1.40
Differential regulation of beta-chemokines in children with Plasmodium falciparum malaria. Infect Immun (2005) 1.37
Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother (2002) 1.36
Elevated nitric oxide production in children with malarial anemia: hemozoin-induced nitric oxide synthase type 2 transcripts and nitric oxide in blood mononuclear cells. Infect Immun (2004) 1.35
Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. Antimicrob Agents Chemother (2006) 1.35
Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis (2004) 1.35
Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J Infect Dis (2004) 1.34
Malaria in pregnancy before and after the implementation of a national IPTp program in Gabon. Am J Trop Med Hyg (2007) 1.34
A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS One (2009) 1.31
Submicroscopic Plasmodium falciparum infections and multiplicity of infection in matched peripheral, placental and umbilical cord blood samples from Gabonese women. Trop Med Int Health (2004) 1.29
Recognition of variant Rifin antigens by human antibodies induced during natural Plasmodium falciparum infections. Infect Immun (2002) 1.27
Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon. Malar J (2008) 1.27
Community response to intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization in five African settings. Malar J (2009) 1.26
Artesunate--amodiaquine combination therapy for falciparum malaria in young Gabonese children. Malar J (2007) 1.23
The sickle cell trait is associated with enhanced immunoglobulin G antibody responses to Plasmodium falciparum variant surface antigens. J Infect Dis (2005) 1.23
The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa. PLoS One (2010) 1.22
Responses to Toll-like receptor ligands in children living in areas where schistosome infections are endemic. J Infect Dis (2004) 1.21
Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis (2010) 1.21
Epidemiology of parasitic co-infections during pregnancy in Lambaréné, Gabon. Trop Med Int Health (2010) 1.20
Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine (2009) 1.19
Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial. Clin Infect Dis (2005) 1.18
Epidemiology of malaria and helminth interaction: a review from 2001 to 2011. Curr Opin HIV AIDS (2012) 1.18
Short-course artesunate treatment of uncomplicated Plasmodium falciparum malaria in Gabon. Antimicrob Agents Chemother (2003) 1.18
Selection of a trioxaquine as an antimalarial drug candidate. Proc Natl Acad Sci U S A (2008) 1.18
Frequency and virulence properties of diarrheagenic Escherichia coli in children with diarrhea in Gabon. Am J Trop Med Hyg (2003) 1.17
Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun (2005) 1.17
Differences in presentation of severe malaria in urban and rural Gabon. Am J Trop Med Hyg (2007) 1.17
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis (2009) 1.16
Angiogenic proteins in brains of patients who died with cerebral malaria. J Neuroimmunol (2003) 1.15
Schistosomes induce regulatory features in human and mouse CD1d(hi) B cells: inhibition of allergic inflammation by IL-10 and regulatory T cells. PLoS One (2012) 1.15
Clinical and parasitological characteristics of puerperal malaria. J Infect Dis (2005) 1.15
In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays. Malar J (2009) 1.14
IFN-gamma and IL-10 mediate parasite-specific immune responses of cord blood cells induced by pregnancy-associated Plasmodium falciparum malaria. J Immunol (2005) 1.14
Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. J Antimicrob Chemother (2007) 1.12
Full blood count and haemozoin-containing leukocytes in children with malaria: diagnostic value and association with disease severity. Malar J (2008) 1.12
Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria. Antimicrob Agents Chemother (2007) 1.12
Decreased circulating macrophage migration inhibitory factor (MIF) protein and blood mononuclear cell MIF transcripts in children with Plasmodium falciparum malaria. Clin Immunol (2006) 1.11
Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria. J Infect Dis (2003) 1.11
Population structure of Staphylococcus aureus from remote African Babongo Pygmies. PLoS Negl Trop Dis (2011) 1.11
Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon. Malar J (2008) 1.10
Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational multicentre study. Malar J (2012) 1.10
New emerging Plasmodium falciparum genotypes in children during the transition phase from asymptomatic parasitemia to malaria. Am J Trop Med Hyg (2002) 1.10
Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. Lancet Infect Dis (2010) 1.10
The association between mannan-binding lectin gene polymorphism and clinical leprosy: new insight into an old paradigm. J Infect Dis (2007) 1.09
Functional haplotypes that produce normal ficolin-2 levels protect against clinical leprosy. J Infect Dis (2009) 1.09
Pregnancy-associated malaria affects toll-like receptor ligand-induced cytokine responses in cord blood. J Infect Dis (2008) 1.07
Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon. Vaccine (2010) 1.07
Comparison of PCR-based detection of Plasmodium falciparum infections based on single and multicopy genes. Malar J (2007) 1.07
A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. PLoS One (2011) 1.06
The impact of malaria on common lipid parameters. Parasitol Res (2002) 1.06
In vitro activity of mirincamycin (U24729A) against Plasmodium falciparum isolates from Gabon. Antimicrob Agents Chemother (2009) 1.06
Plasmodium vivax malaria in Duffy-negative individuals from Ethiopia. Trans R Soc Trop Med Hyg (2013) 1.05
In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum. Am J Trop Med Hyg (2006) 1.05
Rapid detection of Pfcrt and Pfmdr1 mutations in Plasmodium falciparum isolates by FRET and in vivo response to chloroquine among children from Osogbo, Nigeria. Malar J (2007) 1.05
No variation in the prevalence of point mutations in the Pfcrt and Pfmdr1 genes in isolates from Gabonese patients with uncomplicated or severe Plasmodium falciparum malaria. Parasitol Res (2006) 1.05
Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D). PLoS One (2011) 1.04
Phylogenetic analysis of human parvovirus B19, indicating two subgroups of genotype 1 in Vietnamese patients. J Gen Virol (2006) 1.04
Mannose-binding lectin gene polymorphisms and hepatitis B virus infection in Vietnamese patients. Mutat Res (2003) 1.02
A Duffy binding-like domain is involved in the NKp30-mediated recognition of Plasmodium falciparum-parasitized erythrocytes by natural killer cells. J Infect Dis (2007) 1.02
Genetic evidence of functional ficolin-2 haplotype as susceptibility factor in cutaneous leishmaniasis. PLoS One (2012) 1.02
A model for estimating total parasite load in falciparum malaria patients. J Theor Biol (2002) 1.02
Accelerated clearance of Plasmodium-infected erythrocytes in sickle cell trait and annexin-A7 deficiency. Cell Physiol Biochem (2009) 1.02
Ficolin-2 levels and FCN2 haplotypes influence hepatitis B infection outcome in Vietnamese patients. PLoS One (2011) 1.02
No rebound of morbidity following intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Gabon. J Infect Dis (2009) 1.01
Effectiveness of quinine monotherapy for the treatment of Plasmodium falciparum infection in pregnant women in Lambaréné, Gabon. Am J Trop Med Hyg (2005) 1.01
Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children. Antimicrob Agents Chemother (2008) 1.01
Is flow cytometry better in counting malaria pigment-containing leukocytes compared to microscopy? Malar J (2009) 1.01
The multiplicity of Plasmodium falciparum infections is associated with acquired immunity to asexual blood stage antigens. Microbes Infect (2008) 1.01
Malaria and asymptomatic parasitaemia in Gabonese infants under the age of 3 months. Acta Trop (2005) 1.00